Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 9/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20404372 | 0.81 | ACACB (0.64) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL8219973 | 0.80 | MAPT (0.64) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL7508153 | 0.79 | ALDH1A1 (0.51) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL18398515 | 0.78 | MAPT (0.67) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL23430866 | 0.77 | MAPT (0.60) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL18412176 | 0.77 | MAPT (0.61) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL20404371 | 0.77 | MAPT (0.61) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL20409449 | 0.77 | MAPT (0.61) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL3032550 | 0.77 | MAPT (0.61) | MAPTMEN1ALOX12KMT2AACACB | |
| SCHEMBL28545817 | 0.76 | ALDH1A1 (0.53) | MAPTMEN1ALOX12KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146960-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | claimed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | claimed |
| CN-118271162-A | Preparation method of 4-isobutoxybenzylamine hydrochloride | 福建福瑞明德药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. | 2022-01-27 | — | — | US | disclosed |
| CN-107848972-B | Process for the preparation of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt and polymorph C | 阿卡蒂亚药品公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10981870-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981871-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2146960-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4247/4885ALOX12 4855/4885 |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | MTAP, CPN1, DNPEP | MAPT 1590/4885MEN1 3262/4885ALOX12 4737/4885 |
| US-10981870-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form | NR3C2, NR2C2, CYP4A22 | MAPT 4854/4885MEN1 4427/4885ALOX12 4840/4885 |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | NR3C2, NR2C2, CYP4A22 | MAPT 4837/4885MEN1 4241/4885ALOX12 4855/4885 |
| US-10981871-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | NR3C2, CYP4A22, NR2C2 | MAPT 4851/4885MEN1 4340/4885ALOX12 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.